Alterity Therapeutics Ltd. (AU:ATH)
ASX:ATH
Want to see AU:ATH full AI Analyst Report?
Top Page
Alterity Therapeutics
(Sydney:ATH)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.01
▲(10.00% Upside)
Action:ReiteratedDate:11/01/25
Alterity Therapeutics faces significant challenges with profitability and cash flow, despite strong revenue growth and a solid equity position. The technical indicators suggest bearish momentum, and the negative P/E ratio highlights ongoing financial struggles. These factors contribute to a low overall stock score.
Positive Factors
Low Leverage / Strong Equity Base
Extremely low debt provides durable financial flexibility and reduces solvency risk, allowing management to prioritize R&D and clinical programs without heavy interest burdens. This conservatism supports multi-quarter funding runway decisions and partnership negotiations.
Negative Factors
Dependence on Equity Financing
Reliance on capital raises creates structural funding risk and potential shareholder dilution, especially if clinical milestones are delayed. Over several quarters this dependence can constrain strategic options and increase vulnerability to capital market conditions.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Equity Base
Extremely low debt provides durable financial flexibility and reduces solvency risk, allowing management to prioritize R&D and clinical programs without heavy interest burdens. This conservatism supports multi-quarter funding runway decisions and partnership negotiations.
Read all positive factors
Alterity Therapeutics (ATH) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$114.19M
Dividend YieldN/A
Average Volume (3M)16.33M
Price to Earnings (P/E)―
Beta (1Y)1.81
Revenue GrowthN/A
EPS Growth62.50%
CountryAU
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding10,875,416,000
10 Day Avg. Volume24,202,939
30 Day Avg. Volume16,327,471
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.51
Price to Sales (P/S)11.76
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.01Price Target Upside0.00%
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$3.30M
Alterity Therapeutics Business Overview & Revenue Model
Company Description
Alterity Therapeutics (ATH) is a biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, primarily targeting conditions such as Parkinson's disease and Alzheimer's disease. The company leverages its prop...
How the Company Makes Money
Alterity Therapeutics does not primarily generate revenue from product sales because it is a clinical-stage company without broadly commercialized therapies. Its funding and income are typically derived from external capital and non-operating sour...
Alterity Therapeutics Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.83M | 5.44M | 4.02M | 3.92M | 5.12M | 4.34M |
| Gross Profit | 3.71M | 5.31M | 3.80M | 3.63M | 4.76M | 3.98M |
| EBITDA | -20.11M | -14.63M | -19.46M | -17.51M | -17.39M | -19.36M |
| Net Income | -14.59M | -12.15M | -19.12M | -13.81M | -12.85M | -15.31M |
Balance Sheet | ||||||
| Total Assets | 56.92M | 46.03M | 19.22M | 27.32M | 41.36M | 33.59M |
| Cash, Cash Equivalents and Short-Term Investments | 49.20M | 40.66M | 12.64M | 15.77M | 34.81M | 28.12M |
| Total Debt | 163.91K | 155.46K | 159.04K | 210.38K | 117.49K | 65.65K |
| Total Liabilities | 2.65M | 3.62M | 5.43M | 4.50M | 5.89M | 3.12M |
| Stockholders Equity | 54.27M | 42.40M | 13.80M | 22.81M | 35.47M | 30.47M |
Cash Flow | ||||||
| Free Cash Flow | -2.36M | -11.45M | -12.61M | -20.04M | -12.43M | -17.34M |
| Operating Cash Flow | -12.98M | -11.45M | -12.61M | -20.04M | -12.34M | -17.33M |
| Investing Cash Flow | 0.00 | -7.50M | -5.72K | -36.46K | -89.15K | -10.47K |
| Financing Cash Flow | 44.44M | 39.67M | 9.22M | 124.34K | 16.30M | 36.69M |
Alterity Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$1.58B | 78.41 | 9.20% | ― | -69.69% | -78.38% | |
56 Neutral | AU$76.58M | -7.57 | -179.37% | ― | ― | 24.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$60.38M | -9.56 | -104.56% | ― | ― | 57.89% | |
43 Neutral | AU$165.21M | -4.28 | -134.14% | ― | ― | -64.71% | |
42 Neutral | AU$28.32M | -6.84 | -49.25% | ― | ― | 25.00% | |
41 Neutral | AU$114.19M | -2.12 | -30.19% | ― | ― | 62.50% |
* Healthcare Sector Average
AU:ATH
Alterity Therapeutics
0.01
0.00
0.00%
AU:ACW
Actinogen Medical
0.05
0.02
70.37%
AU:CYP
Cynata Therapeutics Limited
0.32
0.13
65.13%
AU:ENP
Tryptamine Therapeutics
0.04
<0.01
19.35%
AU:1AI
Living Cell Technologies
0.01
<0.01
40.00%
AU:NEU
Neuren Pharmaceuticals Limited
12.47
0.17
1.38%
Alterity Therapeutics Corporate Events
Alterity advances ATH434 toward Phase 3 in Multiple System Atrophy after FDA backing
Apr 30, 2026
Alterity Therapeutics reported steady progress in advancing its lead candidate ATH434 toward a pivotal Phase 3 program in Multiple System Atrophy, highlighted by two positive Type C interactions with the U.S. Food and Drug Administration that endo...
Alterity Therapeutics Sets Virtual General Meeting for May 29, 2026
Apr 29, 2026
Alterity Therapeutics has called a virtual General Meeting of shareholders to be held on 29 May 2026 at 12:00pm AEST via the Automic online platform. The notice of meeting and explanatory materials are available on the company’s website and ...
Alterity Wins FDA Backing on CMC Plan for ATH434 Phase 3 in Multiple System Atrophy
Apr 26, 2026
Alterity Therapeutics has secured positive feedback from the U.S. Food and Drug Administration following a second Type C meeting on its planned Phase 3 program for ATH434 in Multiple System Atrophy, a rare neurodegenerative disorder with no approv...
Alterity’s ATH434 Shows Phase 2 Efficacy Signal in MSA on New Composite Scale
Apr 22, 2026
Alterity Therapeutics has unveiled new analyses from its Phase 2 trial of ATH434 in Multiple System Atrophy, showing the drug reduced functional decline versus placebo over 52 weeks on MuSyCA, a newly developed composite scale that captures both d...
Alterity Therapeutics Names Ann Cunningham to Board With No Initial Shareholding
Apr 21, 2026
Alterity Therapeutics has announced the appointment of Ann Cunningham as a director of the company, effective 17 April 2026, in accordance with ASX disclosure rules. The initial director’s interest notice confirms that Cunningham holds no re...
Alterity Therapeutics Grants 27 Million Unlisted Options Under Incentive Scheme
Apr 20, 2026
Alterity Therapeutics has issued 27,000,000 unlisted options with an exercise price of $0.009, expiring on 15 April 2031, as part of its employee incentive arrangements. The move underscores the company’s reliance on equity-based compensatio...
Alterity Therapeutics Issues 212 Million Unlisted Options Under Employee Incentive Plan
Apr 20, 2026
Alterity Therapeutics has issued 212,250,000 unlisted options as part of an employee incentive scheme, with each option carrying an exercise price of US$0.006 and expiring on April 15, 2031. The move expands the company’s pool of unquoted eq...
Alterity Therapeutics Adds Veteran Biotech Executive Ann Cunningham to Board
Apr 17, 2026
Alterity Therapeutics has appointed seasoned biotech executive Ann Cunningham as an independent Non-Executive Director, bolstering its Board as the company advances its lead drug candidate ATH434 toward Phase 3 development in Multiple System Atrop...
Alterity to Spotlight ATH434 MSA Data in Late-Breaker at AAN Meeting
Apr 16, 2026
Alterity Therapeutics said its chief medical advisor, Vanderbilt neurologist Daniel Claassen, will deliver a late-breaking oral presentation at the American Academy of Neurology Annual Meeting in Chicago on April 21. The talk will focus on ATH434&...
Alterity Therapeutics Showcases ATH434 Progress in Virtual MSA KOL Event
Apr 15, 2026
Alterity Therapeutics will host a virtual key opinion leader event to present new insights on its lead candidate ATH434 for the treatment of Multiple System Atrophy, highlighting its potential as a first-in-class, disease-modifying therapy for thi...
Alterity Flags Risks Around Forward‑Looking Corporate Outlook
Apr 1, 2026
Alterity Therapeutics has released a corporate presentation dated April 2026 that includes cautionary language regarding forward‑looking statements. The company emphasizes that projections and statements about its plans, objectives, expectat...
Alterity Wins FDA Backing on Key Elements of ATH434 Phase 3 Plan
Mar 29, 2026
Alterity Therapeutics has received positive written feedback from the U.S. Food and Drug Administration following a Type C Meeting on its planned Phase 3 development program for ATH434 in Multiple System Atrophy. The regulator supported the compan...
Alterity Therapeutics to Issue 61.5 Million Unlisted Options Under Incentive Plan
Mar 26, 2026
Alterity Therapeutics has notified the market of the planned issue of 61,500,000 unlisted options under its employee incentive scheme. The options, which carry an exercise price of US$0.0057 and expire on March 26, 2031, are not intended to be quo...
Alterity Therapeutics Plans Issue of 150 Million Options on ASX
Mar 19, 2026
Alterity Therapeutics has notified the ASX of a proposed issue of up to 150 million options as part of a placement or similar capital-raising structure. The new options will carry an exercise price of A$0.02 and will expire five years after their ...
Alterity Therapeutics Launches Facility to Sell Small Share Parcels
Mar 12, 2026
Alterity Therapeutics has introduced an opt-out unmarketable parcel sale facility for shareholders holding less than A$500 worth of its fully paid ordinary shares, aiming to give these investors a cost-free way to exit positions that might otherwi...
Alterity Therapeutics Highlights Late-Stage Neurodegenerative Pipeline at Bell Potter Summit
Mar 9, 2026
Alterity Therapeutics, a clinical-stage biotech focused on disease-modifying treatments for Multiple System Atrophy and related Parkinsonian disorders, is advancing its lead asset ATH434 following positive Phase 2 data and leveraging a discovery p...
Alterity Therapeutics Taps Vanderbilt Neurologist as Chief Medical Advisor Ahead of Phase 3 MSA Trial
Mar 3, 2026
Alterity Therapeutics has appointed neurologist and movement disorder expert Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor, while he maintains his professorship at Vanderbilt University Medical Center. Claassen, an internationally recog...
Alterity Widens Half-Year Loss but Lifts Asset Backing on Higher Interest Income
Feb 26, 2026
Alterity Therapeutics reported a sharp increase in half-year revenue to A$909,750 for the six months to 31 December 2025, driven entirely by higher interest income on its bank balances, while remaining a pre-revenue biotech with no dividend paymen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.